With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.
Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute, explains the goals and patient population included in the EMPACT-MI trial.
Presented at the European Society of Cardiology (ESC) Congress 2023, EMPACT-MI is testing the safety and benefit of empagliflozin to reduce heart failure hospitalization or all-cause mortality in patients post myocardial infarction (MI).
Transcript
Can you give our audience an overview of your presentation on the EMPACT-MI trial?
There has been really no therapy that has shown risk reduction in post-MI heart failure development. We do know that once you develop heart failure, your 5-year mortality risk equals or exceeds about 50%, so anything to prevent heart failure is really important and myocardial infarction is one of the biggest risk factors. The data would suggest—epidemiologic data—that a quarter to a third of the patients post-MI develop heart failure, so prevention of heart failure is really, really important.
SGLT2 inhibitors have been shown to prevent heart failure in patients with CKD [chronic kidney disease] and diabetes, and MI patients are sort of an enriched population, but (A) we need to prove it, but (B) there are safety concerns also. The post-MI patients get procedures, an [intravenous] contrast, a new RAAS [renin-angiotensin-aldosterone system] inhibitor, a new MRA [mineralocorticoid receptor antagonist], and now SGLT2 inhibitor, so we need to see what the safety and what the benefit profile is.
That was being tested in the EMPACT-MI trial, a large trial, 6000 patients, about three-fourths STEMI [ST-elevation MI patients] and about one-fourth non-STEMI patients enriched for heart failure. So either new onset [MI], drop in EF [ejection fraction], or signs or symptoms of congestion. People with history of heart failure [prior to MI] were excluded. The trial has completed enrollment, is in the follow-up phase, and anxiously awaiting results and we'll get the results hopefully pretty soon in the next few months.
This transcript has been lightly edited for clarity.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More